Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Overview: Collegium is a biopharmaceutical company focused on ADHD and pain management products. The reporting period was significantly impacted by the acquisition of Azstarys (an ADHD treatment) on May 12, 2026, for approximately $655.6 million in cash. The company's portfolio includes Jornay PM, Azstarys, Belbuca, Xtampza ER, Nucynta products, and Symproic.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
|---|---|---|
| Product Revenues, Net | $199,878 | $393,398 |
| Gross Profit | $110,292 | $227,538 |
| Operating Income | $3,698 | $34,594 |
| Net (Loss) Income | $(15,051) | $(555) |
| Diluted EPS | $(0.46) | $(0.02) |
| Operating Cash Flow | N/A | $128,436 |
| Cash & Equivalents (Balance Sheet) | $129,467 | $129,467 |
| Total Debt (Term Notes + Convertible) | $1,091,557 | $1,091,557 |
Note: Total Debt includes $852,824 in Term Notes (carrying value) and $238,733 in Convertible Senior Notes (carrying value).
Material Changes vs. Prior Period
- Revenue Growth: Net product revenues increased 6.3% year-over-year for the quarter ($199.9M vs. $188.0M) and 7.6% for the six-month period ($393.4M vs. $365.8M). Growth was driven by the Azstarys acquisition ($12.9M contribution), increased Jornay PM sales, and higher Belbuca revenue, partially offset by declines in Nucynta and Xtampza ER due to generic competition and authorized generic launches.
- Profitability Decline: Net income turned to a loss of $15.1M for the quarter (vs. $12.0M profit in Q2 2025) and a minimal loss of $0.6M for the six months (vs. $14.4M profit in 2025). This was primarily due to a $23.3M increase in acquisition-related expenses and higher intangible asset amortization ($63.0M vs. $55.5M) associated with the Azstarys deal.
- Balance Sheet Impact: Total assets increased to $2.14B from $1.66B at year-end 2025, driven by $635M in acquired intangible assets and $190M in goodwill. Cash decreased from $231M to $129M due to the acquisition funding and working capital changes.
- Debt Structure: The company refinanced its debt in December 2025 and drew a $300M delayed draw term loan in May 2026 to fund the Azstarys acquisition. Outstanding principal on the 2025 Term Loan is $865.5M.
Guidance, Outlook, and Risks
- Outlook: Management believes current cash, cash equivalents, and operating cash flows will fund operations and debt service for the foreseeable future. No specific numerical guidance for full-year 2026 revenue or earnings was provided in the text.
- Acquisition Integration: The company is integrating Azstarys operations. Success depends on realizing synergies and managing integration costs, which are expected to continue in the remainder of 2026.
- Key Risks:
- Intellectual Property Litigation: Ongoing patent disputes with Purdue (Xtampza ER, Nucynta) and generic competitors (Alvogen, Ascent Pharmaceuticals regarding Belbuca). Outcomes could impact market exclusivity.
- Debt Covenants: The 2025 Credit Facility includes leverage and fixed charge coverage covenants. Failure to comply could trigger an event of default.
- Regulatory & Opioid Risks: Continued scrutiny of opioid marketing, potential changes to REMS requirements, and state/federal opioid taxes.
- Supply Chain: Reliance on third-party manufacturers and potential shortages of active pharmaceutical ingredients (e.g., methylphenidate for ADHD products).
- Unusual Items: Significant one-time costs included $28.4M in acquisition-related expenses for the six months ended June 30, 2026, and $1.4M in executive transition expenses.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the 2025 Credit Facility's leverage and fixed charge coverage ratios given the increased debt load from the Azstarys acquisition.
- Acquisition Synergies: Monitor the integration progress of Azstarys and whether the projected revenue growth materializes to offset the increased amortization and interest expenses.
- Patent Litigation Status: Review updates on the Purdue (Xtampza/Nucynta) and Alvogen/Ascent (Belbuca) litigation, as adverse rulings could significantly reduce future revenue streams.
- Generic Competition: Assess the impact of the authorized generic Nucynta launch and potential future generic entries on the core opioid portfolio margins.
- Cash Burn vs. Generation: Confirm that operating cash flow remains sufficient to service the $865.5M term loan and $241.5M convertible notes without requiring immediate equity dilution.